Mark M. Awad, MD, PhD, discusses the characterization of patients with non–small cell lung cancer who have MET exon 14 skipping alterations and potential acquired resistance mechanisms.
Mark Awad, MD, PhD
Advertisement
Articles by Mark Awad, MD, PhD
Mark Awad, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses the impact of MET inhibitors on survival among patients with <em>MET</em> exon 14-mutant non–small cell lung cancer.
Advertisement
Latest Updated Articles
Investigating MET Exon 14 Mutations in Patients With NSCLCPublished: May 29th 2020 | Updated:
Impact of MET Inhibitors in MET Exon 14-Mutant NSCLCPublished: June 22nd 2017 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
